The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study)
Abstract
Background: Ocular lesions, the main morbidity of Behcet’s disease (BD), are the most difficult to treat. The aim of this study was to evaluate the efficacy of rituximab. Methods: Inclusion criteria were retinal vasculitis and edema, resistant to cytotoxic drugs. Twenty patients were randomized to a rituximab group (RG) or cytotoxic combination therapy group (CCTG). Rituximab was given in two 1000‐mg courses (15‐day interval). Subjects received methotrexate (15 mg/weekly) with prednisolone (0.5 mg/kg per day). The CCTG received pulse cyclophosphamide (1000 mg/monthly), azathioprine (2–3 mg/kg per day) and prednisolone (0.5 mg/kg per day). The primary endpoint was the overall state of patients’ eyes and the Total Adjusted Disease Activity Index (TADAI). Secondary endpoints were: visual acuity (VA), posterior uveitis (PU), and retinal vasculitis (RV). The baseline data were compared at 6 months by paired sample t‐test and analysis of variance. Results: TADAI improved significantly in the RG (t = 3.340, P = 0.009), but not in the CCTG (t = 2.241, P = 0.052). For secondary endpoints (RG/CCTG), the mean VA improved in two patients versus three (2/3), remained unchanged in 1/1, and worsened in 7/6 patients. The mean PU improved significantly in the RG (t = 3.943, P = 0.001), not in the CCTG (t = 2.371, P = 0.028). RV improved, but not statistically (t = 2.027, P = 0.057 vs. t = 1.045, P = 0.31). Edema of retina, disc and macula improved significantly in both, but much better for the RG (t = 2.781, P = 0.012 vs. t = 2.707, P = 0.014). Conclusion: Rituximab was efficient in severe ocular manifestations of BD, TADAI improved significantly after 6 months with rituximab, but not with CCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Cited by
Understanding uveitis: The impact of research on visual outcomes
de Smet, M. D., Taylor, S. R. J., Bodaghi, B., Miserocchi, E., Murray, P. I., Pleyer, U., Zierhut, M., Barisani-Asenbauer, T., LeHoang, P., & Lightman, S. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.06.005 · Cited by 340
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis
Dick, A. D., Rosenbaum, J. T., Al-Dhibi, H. A., Belfort, R., Brézin, A. P., Chee, S. P., Davis, J. L., Ramanan, A. V., Sonoda, K.-H., Carreño, E., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.11.017 · Cited by 285
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Rituximab for Non-Infectious Uveitis and Scleritis
Ng, C. C., Sy, A., & Cunningham, E. T. (2021) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-021-00252-4 · Cited by 40
Metadata
- Authors
- DAVATCHI, F., SHAMS, H., REZAIPOOR, M., SADEGHI‐ABDOLLAHI, B., SHAHRAM, F., NADJI, A., CHAMS‐DAVATCHI, C., AKHLAGHI, M., FAEZI, T., & NADERI, N.
- Venue
- International Journal of Rheumatic Diseases
- Publisher
- Wiley
- Published
- 2010-08
- Volume
- 13
- Issue
- 3
- Pages
- 246-252
- ISSN
- 1756-1841 (ISSN-L)
- 1756-185X
- OpenAlex
- W2142473469
- Cited by
- 229
- References
- 2
- FWCI
- 15.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study). https://app.cochat.ai/papers/10.1111/j.1756-185x.2010.01546.x
- The paper
- DAVATCHI, F., SHAMS, H., REZAIPOOR, M., SADEGHI‐ABDOLLAHI, B., SHAHRAM, F., NADJI, A., CHAMS‐DAVATCHI, C., AKHLAGHI, M., FAEZI, T., & NADERI, N. (2010). Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study). International Journal of Rheumatic Diseases. https://doi.org/10.1111/j.1756-185x.2010.01546.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.